Objective. The aim was to evaluate the predictive value of the baseline multi-biomarker disease activity (MBDA) score in long-standing RA patients with low disease activity tapering TNF inhibitors (TNFi) for successful tapering or discontinuation, occurrence of flare and major flare, and radiographic progression.
Introduction
RA is a chronic inflammatory disease that requires frequent monitoring of disease activity to achieve tight control by setting a treatment target and changing treatment accordingly [1] . The DAS28, based on ESR or CRP, is currently the most widely used measure of RA disease activity [2] . In either version, DAS28 is a composite measure that includes 28 tender and swollen joint counts, patient global assessment by visual analog scale and a laboratory measure of inflammation.
Although use of the DAS28 for treating to target has been extensively validated, there are possible drawbacks to DAS28, as for any composite disease activity measure. Clinical assessments are subject to interobserver variability, resulting in measurement error and suboptimal precision [3, 4] . Also, DAS28 can be influenced by factors other than RA disease activity (e.g. OA, FM or other causes of inflammation, such as infection), resulting in clinical misclassification of disease activity state. Additionally, ongoing subclinical disease activity can cause long-term damage in RA patients who are classified as having low disease activity or remission according to DAS28 [5] . Finally, joint examination requires face-to-face contact and time with trained personnel, which may hamper feasibility in some settings. It would thus be desirable to have tools that are more objective and convenient than those currently used for measuring RA disease activity. Biomarkers could be promising candidates.
Biomarkers have the potential for smaller measurement error than clinical measures, and measuring serum markers may be less costly and more feasible than face-toface contact with full joint counts. Biomarkers could potentially be better for detecting subclinical disease activity and, consequently, predicting risk for radiographic damage. Potential drawbacks of serum biomarkers include laboratory measurement error and misclassification, as biomarker levels may sometimes be affected by factors other than RA [6, 7] . Lastly, despite the inherent desirability of objective measurement, it is currently expected that for a measure of RA disease activity to have good face, content and construct validity, it needs to include a patient perspective on disease activity. This approach contrasts with the reductionist laboratory measurement approach, although both approaches may be complementary.
The multi-biomarker disease activity (MBDA) blood test combines the serum concentrations of 12 protein biomarkers in an algorithm to provide a score that quantifies RA disease activity on a scale of 1100. The MBDA score was designed to correlate with DAS28-CRP, although the two can be discordant [810] . The MBDA score often detects elevated disease activity when DAS28-CRP or CRP does not [1113] . In a study of RA patients receiving ongoing treatment with non-biologic DMARDs (median disease duration 4.6 years), including those in remission or with low disease activity, the MBDA score was a stronger predictor of future radiological progression than the DAS28-CRP [11, 12] . In patients with early RA initiating MTX treatment, the MBDA score predicted development of radiographic progression [13] independently of DAS28.
It therefore seems possible that the MBDA score might be complementary to conventional clinical disease activity assessments.
Treatment strategies in established RA are shifting toward dose optimization, which includes dose tapering of biologic DMARDs (bDMARDs) when remission or low disease activity is reached. Hitherto, no predictive factors for treatment reduction have been validated. Thus, the MBDA score might potentially be of help in identifying patients who could successfully taper or discontinue their bDMARD.
In the present study, therefore, we investigated the clinical utility of the MBDA score in patients with longstanding RA and low disease activity, who were randomly assigned to either taper their TNF inhibitor (TNFi) or continue treatment [14] , by evaluating the capability of the MBDA score to predict successful tapering and discontinuation, the occurrence of flare or major flare and radiographic progression.
Methods

Study population and design
Baseline serum samples and clinical and radiographic outcomes were used from the Dose REduction Strategy of Subcutaneous TNF inhibitors (DRESS) study (Dutch Trial Register, www.trialregister.nl, NTR 3216), an 18-month, open randomized clinical trial that investigated non-inferiority of a dose reduction strategy of adalimumab or etanercept compared with usual care (UC) [14] . The study was performed at the Sint Maartenskliniek in Nijmegen and Woerden, The Netherlands, from December 2011 to May 2014, and was approved by the local ethics committee (CMO region Arnhem-Nijmegen, NL37704.091.11). The ethical approval was for the DRESS study as well as the collection of serum samples and radiographs for future studies. No separate ethical approval was required for the present study. Consenting patients with RA (2010 ACR RA criteria and/or 1987 RA criteria and/or clinical diagnosis by the treating rheumatologist), treated with adalimumab or etanercept at a stable dose for at least 6 months and with stable low disease activity at two consecutive visits, were included. Randomization took place by a research physician who allocated patients to the taper group or UC group in a ratio of 2:1, using a randomization list generated by computer, stratified for adalimumab and etanercept.
All patients were treated according to tight control, with visits scheduled every 3 months up to month 18. Starting at baseline, etanercept and adalimumab injection intervals were increased every 3 months in the dose-tapering group. For adalimumab, which was being administered at enrolment as 40 mg every 14 days, the steps were as follows: 40 mg every 21 days starting from baseline, 40 mg every 28 days starting from month 3, then discontinuation at month 6. For etanercept, which was being administered at enrolment as 50 mg every 7 days, steps were as follows: 50 mg every 10 days, 50 mg every 14 days, then discontinuation. In the control group, patients were treated according to usual tight control care. If patients experienced worsening of disease activity, an extra visit was planned. NSAIDs and intramuscular and intraarticular steroids were allowed, and a follow-up visit after 4 weeks was advised. In the case of a flare persisting after 4 weeks, the last effective TNFi dosing interval was reinstated; if no improvement of disease activity occurred, TNFi was increased stepwise, if needed, to the shortest registered interval [14] . If a flare persisted thereafter, treatment was switched. Only one attempt at tapering was made per patient.
Clinical measurements
The predictive value of the baseline MBDA score was evaluated for five clinical outcome measures in the following three categories relevant to TNFi dose reduction: successful dose tapering or discontinuation; occurrence of flare or major flare; and occurrence of radiographic progression. Successful tapering was defined at 18 months as using the TNFi at a longer interval or lower dose than at enrolment, with concurrent low disease activity and absence of flare. Occurrence of a flare was defined according to a previously validated criterion: a DAS28-CRP increase of >1.2 compared with baseline or a DAS28-CRP increase of >0.6 compared with baseline and current DAS28-CRP 53.2 [15] . Major flare was defined as a flare persisting >3 months. Thus, a flare was defined before administration of any treatment for the flare, whereas a major flare was defined after up to 3 months of such treatment. For patients with multiple flares, only the first flare was considered for analyses.
Biomarker measurement and the MBDA test Serum samples were collected at baseline, processed within 2 h after blood collection and stored in standard separator tubes at À80 C. One or two freezethaw cycles were required to prepare the samples for shipping. All samples were shipped frozen to Crescendo Bioscience (South San Francisco, CA, USA) for MBDA testing in the Clinical Laboratory Improvement Amendments certified laboratory that is used for the Vectra Õ DA test. The 12 biomarkers measured were as follows: VCAM-1 (Vascular Cell Adhesion Molecule-1), Epidermal Growth Factor, VEGF-A, IL-6, TNF-RI (Tumor Necrosis Factor Receptor, Type 1), MMP-1, MMP-3, YKL-40 (Human Cartilage Glycoprotein 39), leptin, resistin, Serum Amyloid and CRP. The MBDA algorithm combines the concentrations of these 12 biomarkers to generate a score on a scale of 1100, with validated categories of <30 for low disease activity, 30À44 for moderate and >44 for high disease activity [6, 10, 16] .
Radiography
Standard radiographs of hands and feet were obtained at baseline and after 18 months. Sharpvan der Heijde (SvdH) scoring was performed by two trained observers, who evaluated X-rays in chronological order and were blinded to the occurrence of flares and medication use. Radiographic progression was defined as a change in SvdH >0.5 points from baseline to month 18 [17] .
The calculated smallest detectable change in SvdH was 4.1 points. For exploratory analyses, radiographic progression was evaluated using definitions of a change in SvdH >3 points and change in SvdH >5 points.
Statistical analyses
Descriptive statistics were done parametrically or non-parametrically, as appropriate, and mean DAS28-CRP and mean MBDA scores at baseline were calculated. Correlations between baseline MBDA score and DAS28-CRP and its subcomponents were assessed by Spearman's r. Disease activity categories (low, moderate and high) according to DAS28-CRP and MBDA score were cross-classified. Agreement was calculated using quadratic weighted Cohen's k. Categories used for DAS28-CRP were <2.7 for low disease activity, 2.7À4.1 for moderate disease activity and >4.1 for high disease activity [18] . All analyses were performed for all patients combined and by randomization group, with the exception of those analyses of successful tapering and successful discontinuation (which apply only to the tapering group) and sensitivity analyses of radiographic progression by 3 or 5 SvdH points (performed only for all patients combined). Analyses of the area under the receiver operating characteristic (AUROC) curves were used to evaluate the predictive value of baseline MBDA score for successful tapering, successful discontinuation, flare, major flare and radiographic progression. KaplanMeier curves were generated for the time to flare using baseline MBDA score categories. Cumulative probability plots were generated to display radiographic progression for each baseline MBDA category. Characteristics of patients with and without missing data were compared. Afterwards, patients with missing data were excluded from further analyses.
Results
Patient baseline characteristics
One hundred and eighty patients participated in the DRESS study, with 121 patients randomized to dose tapering and 59 patients to UC. Of these patients, 171 (115 tapering, 56 UC) had baseline and outcome measures available, 8 patients had no baseline serum sample and 1 patient had no 18-month clinical outcome data. Baseline characteristics were comparable between patients with and without missing data. For the 171 patients in the present analyses, mean (S.D.) age was 59.0 years (9.7), 63% were female, and median disease duration was 10 years (25À75 percentile, 6À16) ( 
Rates of radiographic progression
Baseline serum samples and radiographic data at baseline and 18 months were available for 167 patients. Median SvdH scores at baseline were 23 and 17.5 in the taper and UC groups, respectively [14] . The mean (S.D.) change in SvdH score was 0.71 (1.5) in the taper group and 0.22 (1.5) in the UC group. Radiographic progression (change in SvdH >0.5) occurred in 43/167 (26%) patients: 34/111 (31%) in the taper group and 9/56 (16%) in the UC group. In the total group, 10/167 (6%) had a change in SvdH >3 and 4/167 (2%) had a change in SvdH >5 points.
Association of MBDA score with DAS28-CRP Spearman correlation between MBDA score and DAS28-CRP at baseline demonstrated a significant but low r value (r = 0.2, P = 0.01; Table 3 ). Correlations of subcomponents of DAS28-CRP with MBDA score at baseline were greatest for CRP (r = 0.60, P < 0.01) and lowest for tender joint count (r = 0.05, P = 0.49; Table 3 ). Cross-classification of baseline MBDA score and baseline DAS28-CRP showed that most patients (81%) had low disease activity by DAS28-CRP, yet 65% had moderate or high MBDA scores (Table 4) . Agreement by Cohen's k with quadratic weighting was 0.02. Fig. S3A and B, available at Rheumatology Online). No association between MBDA category and flare was present in the taper group. In the UC group, a trend toward an association of greater MBDA score with more frequent flares was observed.
Radiographic progression
AUROC for predicting radiographic progression of >0. Fig. S4A and B, available at Rheumatology Online). AUROCs for predicting progression by SvdH cut-off values of 3 and 5 points in the total group were also non-significant (Table 5) . Cumulative probability plots of radiographic progression (i.e. change in SvdH from baseline to 18 months) for the low, moderate and high categories of baseline MBDA score demonstrated no association between MBDA category and progression rate in the taper group and a trend toward greater progression among patients with high MBDA score in the UC group (supplementary Fig. S5 , available at Rheumatology Online).
Discussion
This is one of the first studies to investigate the MBDA score in patients with long-standing RA who tapered TNFi treatment. Our primary findings are that the MBDA Low  48  66  24  138  Moderate  11  14  5  30  High  0  2  1  3  Total  59  82  30  171 Weighted (quadratic) Cohen's k was 0.02. MBDA: multi-biomarker disease activity.
TABLE 5
Prediction analyses (area under receiver operating characteristic curves) using baseline multi-biomarker disease activity score www.rheumatology.oxfordjournals.org score before the initiation of tapering was not predictive of successful tapering or stopping of TNFi treatment, occurrence of flare or major flare or radiographic progression in the clinical context of DRESS, a study of long-standing RA patients tapering TNFi under tight control [14] . Our findings seem robust and valid, at least in this specific context. The design, determinant and outcome measurements, analyses and reporting used for this diagnostic prediction study closely follow STARD recommendations [19] . Although this study was not a priori powered for these analyses, the sample sizes appear to be reasonable, as witnessed by sufficiently narrow CIs. Finally, most of our analyses show similar results.
Some misclassification of successful dose tapering or discontinuation may be present in this study. Although we used a previously validated flare criterion in the study protocol [15] , a proportion of patients could have been falsely classified as being unable to taper or stop if, for example, their continuation of TNFi treatment was because of fear of flaring (by patient or rheumatologist) rather than real flare symptoms. This effect could have caused a bias towards lower correlation measures, but it seems unlikely that it would have caused the null results that were found. It is possible that treatment administered for flares altered the relationship between baseline MBDA score and the subsequent declaration of major flares, potentially explaining that negative finding. However, the relationship between simple flares and MBDA score should not have been comparably affected.
A borderline positive predictive value of baseline MBDA score for major flare was found in the entire UC group and for flare and major flare in UC patients who had low disease activity at baseline. These results should be interpreted cautiously as they may be false-positive findings attributable to multiple testing. In addition, the association with major flare in the tapering group was nearly significant in the opposite direction (higher MDBA score associated with less flare). Review of medication use (sDMARDs and steroids) during the trial does not indicate that patients in the taper group were treated more aggressively in anticipation of flare, which if true, might have caused flares to be less prevalent and less severe in that arm [14] . Also, in this scenario we might have found significant AUROCs for flares, which were untreated, whereas we found only a non-significant trend in the UC group.
The capability of the MDBA score to predict outcomes after reduction of RA treatment has been evaluated in two other studies, Reduction of Therapy in patients with Rheumatoid arthritis in Ongoing remission (RETRO) and Potential Optimalisation of (Expediency and) Effectiveness of TNF blockers (POET) [20, 21] . Both studies differed from DRESS in several ways, and both reported the MBDA score to be a significant predictor of outcomes.
Rech et al. [20] described the predictive value of the MBDA score for relapse in RETRO, a three-arm, 12-month randomized controlled trial of dose tapering and discontinuation of bDMARDs and sDMARDs for RA patients in sustained DAS28 remission. The MBDA score and ACPA was each predictive for relapse vs remaining in remission, with improved predictive value when they were used together. Interpretation of this result needs to consider that all RA medications, including bDMARDs, sDMARDs and low-dose steroids, were tapered in RETRO, with or without subsequent discontinuation. Moreover, only one-third of patients in the treatment reduction arms were using a bDMARD, which included TNFi and tocilizumab. Thus, it is unclear which tapered medications were responsible for the predictive ability of MBDA score or ACPA in that cohort [20] . Relapse was more frequent in RETRO than major flares were in DRESS, possibly because of the different reduction strategies and definitions for loss of response. In DRESS, neither MBDA score nor ACPA was predictive of flares following TNFi tapering [14] .
A subanalysis of POET showed that the MBDA score was a predictor for flare after TNFi discontinuation during 12 months of follow-up [21] . POET enrolled patients with long-standing RA, like DRESS, and with a requirement of stable low disease activity by DAS28 while receiving adalimumab or etanercept. Only patients who were randomized to discontinuation were included in the subanalyses. The sample size in the analysis of MBDA score in POET was large (n = 439). The primary clinical objective of POET used a DAS28-based flare criterion that was not included in the analyses of prediction by MBDA score [21, 22] . The four flare definitions that were used for the prediction analyses were based on physician/patient judgement or decision [21] . The occurrence of a flare in POET increased from $60 to 80% between patients with low vs high baseline MBDA score, suggesting that, in that context, the MBDA score was most applicable for predicting who was at greatest risk of flare, and not who was at low risk. Results of RETRO and POET are intriguing, but comparing them with DRESS is difficult owing to differences in design and analyses.
Our finding that radiographic progression was not associated with baseline MBDA score in DRESS disagrees with five studies in four cohorts of patients with established RA [11, 12, 23] or early RA [13, 24] . The different results might be attributable to the low frequency and severity of radiographic progression in our study, with only a small difference in favour of the UC group. It might reflect the strict tight control that was applied to patients who were already in low disease activity or remission. Moreover, several variables that may have driven radiographic progression in DRESS (tapering with associated flaring, temporary increases in disease activity, and reduced TNFi use) occurred after baseline and may have disconnected radiographic progression from the baseline MBDA score. The MBDA score was also reported to not be associated with radiographic progression among patients treated with abatacept or adalimumab in the Abatacept versus Adalimumab Comparison in BiologicNaive RA Subjects with Background Methotrexate (AMPLE) study [25] . This conclusion was based on an analysis that presented the distribution of radiographic non-progressors across the low, moderate and high MBDA categories, rather than the frequency of radiographic non-progressors within MBDA categories. A subsequent re-analysis of the same data from AMPLE used, instead, an approach similar to that of previous MBDA analyses and demonstrated that the MBDA score was positively associated with radiographic progression in AMPLE, although numbers of patients with progression were low [26] . Additional data from AMPLE supported the findings of this re-analysis [27] . This positive relationship between MBDA score and radiographic progression in AMPLE is thus consistent with the results of other studies which, unlike DRESS, did not use a tapering strategy [1113, 23, 24] .
In summary, the baseline MBDA score was not found to be a predictor of flare-related outcomes for patients tapering TNFi in the clinical context of DRESS, a study of disease activity-guided TNFi tapering in patients with long-standing RA under tight control. It is conceivable that in different contexts, for example in early RA patients, patients with higher levels of disease activity, or circumstances with less than optimal tight control, the MBDA score might have predictive value for relevant clinical outcomes. Confirmatory research of these findings is warranted.
